Publikace
- Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters2019 | Farmaceutická fakulta v Hradci Králové
- Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance2019 | Farmaceutická fakulta v Hradci Králové
- Toxicity of the mycotoxin ochratoxin A in the light of recent data2013 | Farmaceutická fakulta v Hradci Králové
- Ochratoxin A: Developmental and Reproductive Toxicity-An Overview2013 | Farmaceutická fakulta v Hradci Králové
- Hledání antituberkulotik o novém mechanismu účinkuPublikace bez příslušnosti k fakultě
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter2022 | Farmaceutická fakulta v Hradci Králové
- Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase2022 | Farmaceutická fakulta v Hradci Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Farmaceutická fakulta v Hradci Králové
Loading network view...